Furthermore, we detected significant increase in the anti-tumor CD8+T-lymphocytes and NK cells, and a decrease in the immune-suppressive populations Mo-MDSC and TAM2 (Fig. 5B) infiltrating the tumor in xenografts treated with atezolizumab combined with lurbinectedin, ecubectedin and PM54, while Pt + PMX did not change significantly compared to animals treated with vehicle. This evidence concerns the gene CD8A and neoplasm.